News from the CGRP Forum

New information on potential cost-effectiveness of CGRP inhibitors and the link between migraine and cardiovascular risk.

US analysis forecasts lower migraine-related costs and more QALYs with erenumab

Mathematical modelling of value-based pricing concludes that, compared with supportive care, preventive treatment of migraine with erenumab is likely to result in lower direct and indirect costs and incremental quality adjusted life years (QALYs).

Read the full report here »

Largest-ever analysis highlights long-term stroke and heart attack risk in migraine

An updated meta-analysis, including over 1 million subjects followed up for up to 26 years, concludes that migraine is associated with a higher long-term risk of cardiovascular and cerebrovascular events — an effect that is due to an increased risk of stroke and heart attack.

Read the full report here »

Burden of migraine falls heaviest on already disadvantaged people

In the USA, severe headache and migraine remain important public health problems that are more common and burdensome for women, particularly women of childbearing age, and other historically disadvantaged segments of the population.

Read the full report here »